Skip to main content
NIH funding notice RFA-AI-23-026

Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed)

Closed on August 2, 2023.

Posted
April 20, 2023
Close date
August 2, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $892,826 in first-year total cost, median $892,826.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 BJM-A (J1)]1

Most frequent institutions

  1. LA JOLLA INSTITUTE FOR IMMUNOLOGY1
Competing awards under RFA-AI-23-026 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024HIV mRNA vaccine strategies for efficient priming, diversity and durability of immune responses1R61AI183471-01RAMEZANI-RAD, PARHAMLA JOLLA INSTITUTE FOR IMMUNOLOGY, CA$892,826ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-AI-23-026: Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed) | ScienceDex | ConductScience